Patent Issued for Compositions and methods comprising SFRP2 antagonists (USPTO 11873333).
In: Women's Health Weekly, 2024-02-06, S. 1784-1784
serialPeriodical
Zugriff:
A patent has been issued for compositions and methods involving SFRP2 antagonists. SFRP2 has been implicated in promoting tumor growth in various cancers, including breast cancer, osteosarcoma, and lung cancer. The patent describes a humanized anti-SFRP2 antibody or antigen binding fragment that binds to SFRP2 and can potentially be used as a therapeutic target for osteosarcoma. The patent also includes claims related to isolated polynucleotides, vectors, host cells, and pharmaceutical compositions. The patent was filed by the University of North Carolina at Chapel Hill. [Extracted from the article]
Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Compositions and methods comprising SFRP2 antagonists (USPTO 11873333).
|
---|---|
Zeitschrift: | Women's Health Weekly, 2024-02-06, S. 1784-1784 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-7240 (print) |
Schlagwort: |
|
Sonstiges: |
|